SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 704.23+1.6%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Miljenko Zuanic5/26/2018 1:22:36 PM
1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) of 3559
 
J&J (Genmab) disconinued development of the anti-CD38 (Darzalex) -IO combination (their in house anti-PD1): ir.genmab.com ( clinicaltrials.gov.

How long will Sanofi/REGN waste time, money, and human resource (and my patience, ready to collapse) before they stop combo development: Isatuximab (their in-house, weak, anti-CD38) + REGN2810??? clinicaltrials.gov

When will Sanofi STOP controlling REGN development pipeline? Or, better Q is: When will REGN BREAK Sanofi grip?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News